Anti‐obesity and anti‐atherogenesis effects of Doenjang supplementation in overweight/obese Korean subjects: A randomized, double‐blind, placebo‐controlled clinical trial

Abstract

To investigated the effects of Doenjang supplementation on anti‐obesity and anti‐atherogenesis in overweight/obese subjects. A total of 51 subjects (26 Doenjang group, 25 Placebo group, both BMI = 23 kg/m2 and WHR = 0.90 (men), WHR = 0.85 (women)) participated in a randomized, double‐blind, placebo‐controlled, oral Doenjang (26g/d)or placebo for 12 weeks. After 12 weeks, subjects in the Deonjang group showed a significant reduced in body weight, BMI, body fat mass, and body fat. CT scans revealed that total and subcutaneous fat areas were significantly reduced in the Doenjang group (p<0.001, p<0.005) and placebo group (p<0.05, p<0.05), but there were no significant differences between placebo and Doenjang group. Visceral fat area was significantly reduced in the Doenjang group (p<0.001) after the intervention, but the placebo group was not changed, thus it was significant difference between placebo and Doenjang group. In addition, total cholesterol level (p<0.05), LDL‐C (p<0.001), Apo B (p<0.001), Fasting plasma glucose and fructosamine concentration were significantly decreased in the Doenjang group and placebo group, but there were no significant differences between placebo and Doenjang group. The results suggested Doenjan supplementation that potential anti‐obesity and anti‐atherogenesis benefits might be more pronounced when combined with lifestyle modification.